Dr Reddy's delayed Semaglutide supplies after certain batches failed quality specifications due to an API issue. The company ...
Dr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing ...
Monday's announcement will see Dr. Reddy's API facility in Hyderabad sold to Therapiva Pvt. Ltd, a JV between a subsidiary of Neopharma Llc (parent of Neopharma Inc.) and Laxai Life Sciences. Photo: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results